539 related articles for article (PubMed ID: 20838622)
1. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
Smith AD; Smith SM; de Jager CA; Whitbread P; Johnston C; Agacinski G; Oulhaj A; Bradley KM; Jacoby R; Refsum H
PLoS One; 2010 Sep; 5(9):e12244. PubMed ID: 20838622
[TBL] [Abstract][Full Text] [Related]
2. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.
Quinn JF; Raman R; Thomas RG; Yurko-Mauro K; Nelson EB; Van Dyck C; Galvin JE; Emond J; Jack CR; Weiner M; Shinto L; Aisen PS
JAMA; 2010 Nov; 304(17):1903-11. PubMed ID: 21045096
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of B Vitamins and Their Interactions with Aspirin in Improving Cognitive Functioning in Older People with Mild Cognitive Impairment: Pooled Post-Hoc Analyses of Two Randomized Trials.
Wu Y; Smith AD; Refsum H; Kwok T
J Nutr Health Aging; 2021; 25(10):1154-1160. PubMed ID: 34866142
[TBL] [Abstract][Full Text] [Related]
4. The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial.
Gommans J; Yi Q; Eikelboom JW; Hankey GJ; Chen C; Rodgers H;
BMC Geriatr; 2013 Sep; 13():88. PubMed ID: 24004645
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapy of Hyperhomocysteinemia in Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementing Disorders.
Hara J; Shankle WR; Barrentine LW; Curole MV
J Nutr Health Aging; 2016; 20(8):825-834. PubMed ID: 27709231
[TBL] [Abstract][Full Text] [Related]
6. The significance of thyroid-stimulating hormone and homocysteine in the development of Alzheimer's disease in mild cognitive impairment: a 6-year follow-up study.
Annerbo S; Wahlund LO; Lökk J
Am J Alzheimers Dis Other Demen; 2006; 21(3):182-8. PubMed ID: 16869339
[TBL] [Abstract][Full Text] [Related]
7. Elevated homocysteine is associated with increased rates of epigenetic aging in a population with mild cognitive impairment.
Holmes HE; Valentin RE; Jernerén F; de Jager Loots CA; Refsum H; Smith AD; Guarente L; Dellinger RW; Sampson D;
Aging Cell; 2024 Jun; ():e14255. PubMed ID: 38937999
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine and cognitive function in elderly people.
Garcia A; Zanibbi K
CMAJ; 2004 Oct; 171(8):897-904. PubMed ID: 15477631
[TBL] [Abstract][Full Text] [Related]
9. Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia.
Price BR; Wilcock DM; Weekman EM
Front Aging Neurosci; 2018; 10():350. PubMed ID: 30429785
[TBL] [Abstract][Full Text] [Related]
10. The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial.
Baltic S; Nedeljkovic D; Todorovic N; Ranisavljev M; Korovljev D; Cvejic J; Ostojic J; LeBaron TW; Timmcke J; Stajer V; Ostojic SM
J Nutr Health Aging; 2024 Jun; 28(8):100287. PubMed ID: 38908296
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine and Mild Cognitive Impairment: Are These the Tools for Early Intervention in the Dementia Spectrum?
Ansari Z
J Nutr Health Aging; 2016 Feb; 20(2):155-60. PubMed ID: 26812511
[TBL] [Abstract][Full Text] [Related]
12. Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial.
Carotenuto A; Andreone V; Amenta F; Traini E
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929542
[No Abstract] [Full Text] [Related]
13. Cerebral perivascular spaces as predictors of dementia risk and accelerated brain atrophy.
Barisano G; Iv M; ; Choupan J; Hayden-Gephart M
medRxiv; 2024 Apr; ():. PubMed ID: 38712073
[TBL] [Abstract][Full Text] [Related]
14. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial.
de Jager CA; Oulhaj A; Jacoby R; Refsum H; Smith AD
Int J Geriatr Psychiatry; 2012 Jun; 27(6):592-600. PubMed ID: 21780182
[TBL] [Abstract][Full Text] [Related]
15. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment.
Douaud G; Refsum H; de Jager CA; Jacoby R; Nichols TE; Smith SM; Smith AD
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9523-8. PubMed ID: 23690582
[TBL] [Abstract][Full Text] [Related]
16. Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial.
Jernerén F; Elshorbagy AK; Oulhaj A; Smith SM; Refsum H; Smith AD
Am J Clin Nutr; 2015 Jul; 102(1):215-21. PubMed ID: 25877495
[TBL] [Abstract][Full Text] [Related]
17. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the Beyond Ageing Project: a randomized controlled trial.
Walker JG; Batterham PJ; Mackinnon AJ; Jorm AF; Hickie I; Fenech M; Kljakovic M; Crisp D; Christensen H
Am J Clin Nutr; 2012 Jan; 95(1):194-203. PubMed ID: 22170358
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.
Basurto-Islas G; Blanchard J; Tung YC; Fernandez JR; Voronkov M; Stock M; Zhang S; Stock JB; Iqbal K
Neurobiol Aging; 2014 Dec; 35(12):2701-2712. PubMed ID: 25034344
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.
Lee KW; Im JY; Woo JM; Grosso H; Kim YS; Cristovao AC; Sonsalla PK; Schuster DS; Jalbut MM; Fernandez JR; Voronkov M; Junn E; Braithwaite SP; Stock JB; Mouradian MM
Neurotherapeutics; 2013 Jan; 10(1):143-53. PubMed ID: 23296837
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase 2A dysfunction in Alzheimer's disease.
Sontag JM; Sontag E
Front Mol Neurosci; 2014; 7():16. PubMed ID: 24653673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
